Jobs
-
The 700-plus OINDP specialists expected to convene at the Edinburgh International Conference Centre December 6-8 for this year’s Drug Delivery to the Lungs (DDL) meeting will notice a few small changes designed to further the… Read more . . .
-
Synairgen has announced that it is considering development of its SNG001 inhaled interferon beta for the treatment of COPD. SNG001 was previously in development for the prevention of exacerbations caused by viral lung infections in… Read more . . .
-
CDMO Micro-Sphere has added a Harro Höfliger Modu-C MS capsule filling machine at its Lugano, Switzerland facility as part of a €19 million expansion, the company said, adding that the new machine offers 100% check… Read more . . .
-
Engage Therapeutics has closed a $23 million Series A financing round led by TPG Biotech that will fund a Phase 2b clinical trial of an inhaled alprazolam for the treatment of acute epileptic seizures. Alexza… Read more . . .
-
CDMO and device company Hovione has announced the appointment of Frédéric Kahn as VP Marketing and Sales. Kahn most recently served as VP Global Head of Key Account Management at Lonza and previously held executive… Read more . . .
-
Savara has announced the initiation of a Phase 3 study of its AeroVanc vancomycin DPI for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. The AVAIL study is expected to… Read more . . .
-
Former Medicon Valley Inhalation Consortium (MVIC) CEO Ola Nerbrink has joined PreciseInhale maker Inhalation Sciences (ISAB) as Senior Sales Advisor, the company said. Nerbrink, who stepped down as MVIC CEO earlier this year, founded Respiron… Read more . . .
-
Galen US has acquired US rights to Alexza Pharmaceuticals’ Adasuve inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar I. Adasuve was approved by the FDA in December 2012 for use… Read more . . .
-
According to Aradigm Corporation, the FDA has accepted its NDA for Linhaliq dual release inhaled ciprofloxacin for the treatment of chronic P. aeruginosa infections in non-cystic fibrosis bronchiectasis (NCFBE) patients for priority review. The agency… Read more . . .
-
4D Molecular Therapeutics (4DMT) has received $3 million from Cystic Fibrosis Foundation Therapeutics (CFFT) for development of 4D-710, an aerosolized adeno-associated virus (AAV) gene therapy vector that will deliver a functional copy of the CFTR… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany